HomeCompareNMFC vs LLY

NMFC vs LLY: Dividend Comparison 2026

NMFC yields 16.80% · LLY yields 0.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LLY wins by $1.47M in total portfolio value· pulled ahead in Year 7
10 years
NMFC
NMFC
● Live price
16.80%
Share price
$7.62
Annual div
$1.28
5Y div CAGR
3.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.4K
Annual income
$7,417.58
Full NMFC calculator →
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →

Portfolio growth — NMFC vs LLY

📍 LLY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMFCLLY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMFC + LLY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMFC pays
LLY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMFC
Annual income on $10K today (after 15% tax)
$1,427.82/yr
After 10yr DRIP, annual income (after tax)
$6,304.94/yr
LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
At 15% tax rate, LLY beats the other by $1,020,099.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMFC + LLY for your $10,000?

NMFC: 50%LLY: 50%
100% LLY50/50100% NMFC
Portfolio after 10yr
$804.6K
Annual income
$607,475.89/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

NMFC
Analyst Ratings
3
Buy
8
Hold
1
Sell
Consensus: Hold
Price Target
$10.00
+31.2% upside vs current
Range: $10.00 — $10.00
Altman Z
0.5
Piotroski
8/9
LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMFC buys
0
LLY buys
0
No recent congressional trades found for NMFC or LLY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMFCLLY
Forward yield16.80%0.70%
Annual dividend / share$1.28$6.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.1%100%
Portfolio after 10y$71.4K$1.54M
Annual income after 10y$7,417.58$1,207,534.19
Total dividends collected$40.9K$1.49M
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$10.00$1,243.95

Year-by-year: NMFC vs LLY ($10,000, DRIP)

YearNMFC PortfolioNMFC Income/yrLLY PortfolioLLY Income/yrGap
1$12,432$1,731.86$10,841$140.53+$1.6KNMFC
2$15,377$2,074.55$11,884$284.74+$3.5KNMFC
3$18,925$2,472.44$13,299$583.47+$5.6KNMFC
4$23,182$2,932.14$15,451$1,220.47+$7.7KNMFC
5$28,266$3,460.76$19,183$2,650.30+$9.1KNMFC
6$34,310$4,065.84$26,676$6,150.32+$7.6KNMFC
7← crossover$41,467$4,755.41$44,530$15,986.45$3.1KLLY
8$49,908$5,537.91$97,527$49,880.25$47.6KLLY
9$59,824$6,422.20$308,551$204,197.51$248.7KLLY
10$71,429$7,417.58$1,537,684$1,207,534.19$1.47MLLY

NMFC vs LLY: Complete Analysis 2026

NMFCStock

New Mountain Finance Corporation (Nasdaq: NMFC), a business development company is a private equity / buyouts and loan fund specializes in directly investing and lending to middle market companies in defensive growth industries. The fund prefers investing in buyout and middle market companies. It also makes investments in debt securities at all levels of the capital structure including first and second lien debt, unsecured notes and mezzanine securities. In some cases, its investments may also include equity interests. It targets energy, specialty chemicals and materials, trading companies and distributors, commercial printing, diversified support services, education services, environmental and facilities services, office services and supplies, media, distributors, health care services, health care facilities, application software, business services, systems software, federal services, distribution and logistics, interactive home entertainment, telecommunication services, hydroelectric power generation, electric power generation by fossil fuels, electric power generation by nuclear fuels, health care technology, and security and alarm services. The fund seeks to invest in United States of America. It seeks to invest between $10 million and $50 million per transaction. The firm invests through both primary originations and open-market secondary purchases. It invests in companies with EBITDA between $10 million and $200 million and target investments up to a $125 million hold size. The fund seeks a majority stake in its portfolio companies.

Full NMFC Calculator →

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →
📬

Get this NMFC vs LLY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMFC vs SCHDNMFC vs JEPINMFC vs ONMFC vs KONMFC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.